VANCOUVER, BC / ACCESSWIRE / March 16, 2017 / OSPREY GOLD DEVELOPMENT LTD. (the “Company” or “Osprey”) (TSX-V: OS) is pleased to announce the results of an updated gold resource estimate for the Goldenville Project (“Goldenville”), located in northeastern Nova Scotia, Canada near the town of Sherbrooke. This estimate has resulted in an Inferred Resource of 2,800,000 tonnes at 3.20 grams per tonne (“g/t”) gold for 288,000 ounces of gold (2,800,000 tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped). The resource estimate was completed by David G. Thomas, M.Sc., P. Geo. and Neil Pettigrew, M.Sc., P. Geo. of Fladgate Exploration Consulting Corporation (“Fladgate”) based in Thunder Bay, Ontario. The updated resource estimate is found in Table 1.1.

The 2017 updated resource yielded an increase of 60% in Inferred ounces (a 72% increase on an uncapped basis). The 2017 resource is classified as entirely Inferred, whereas the 2005 resource included both indicated and inferred resources. For a comparison with the previously disclosed 2005 43-101 resource entitled, “Technical Report on Mineral Resource Estimate – Acadian Gold Corporation – Goldenville Property – Guysborough County, Nova Scotia, Canada” was prepared for Acadian Gold Corporation by Mercator Geological Services Limited. (the “Acadian Gold Technical Report”), see Table 1.2 below.

Table 1.1 – Goldenville Inferred Mineral Resource Estimate, David Thomas, P. Geo. (Effective Date: March 15, 2017)

Resource Type
Tonnage (t)
Au (g/t)
Au (Oz)
Near Surface (0.75 g/t Cut-Off)
1,240,000
3.02
120,000
Underground (2.00 g/t Cut-Off)
1,560,000
3.35
168,000
Total
2,800,000
3.2
288,000

Table 1.2 – Comparison with previous 43-101 resource estimate (from the Acadian Gold Technical Report)

Year
Category
Cut-Off (g/t)
Tonnage (t)
Au (g/t)
Capped
Au (g/t)
Uncapped
Au (Oz)
Capped
Au (Oz)
Uncapped
2005*
Indicated
1.00
181,047
6.31
6.96
37,729
40,517
2005*
Inferred
1.00
855,025
6.54
9.43
179,783
259,257
2017
Indicated
–
–
–
–
–
–
2017
Inferred
Multiple**
2,800,000
3.20
4.96
288,000
447,000

Footnotes to mineral resource statement:

Mineral resources are not mineral reserves and do not have demonstrated economic viability. No mineral reserves have as yet been defined. Inferred mineral resources are considered too speculative geologically to have the economic considerations applied to them that would enable them to be considered for estimation of mineral reserves, and there is no certainty that the inferred mineral resources will be realized.

Fladgate undertook data verification, and reviewed historical quality assurance and quality control programs on the mineral resources data. Fladgate concluded that the collar, survey, assay, and lithology data were adequate to support mineral resources estimation.

A dry bulk density value of 2.67 g/cm3 for all material was assigned from similar Meguma-type gold mineralization with similar rock types in Nova Scotia.

Fladgate assumed a metallurgical recovery of 90% based on a qualitative assessment of the gold mineralogy and grain size.

Near surface mineral resources are constrained within an open pit shell optimized with an L-G algorithm. A process and G&A cost of $25 and a mining cost of $3.00/tonne have been used.

Underground resources have been constrained within a grade shell using a 2.0 g/t threshold, assuming a mining cost of $50/tonne in addition to the operating costs. Isolated blocks were removed from the grade shell. The mineral resources have been depleted using solids representing underground development and areas of stoping for post 1920’s historical mining for which technical drawings are available, however no records are available for the abundant, pre 1920’s mining development, which is known to have occurred throughout the property.

Blocks were classified as inferred in accordance with CIM Definition Standards.

The contained metal figures shown are in situ. The resource estimation methodology incorporates a significant amount of external and internal dilution due to the use of 2 meter composites, probabilistic domaining and the grade smoothing introduced by ordinary kriging with a variogram which has a short range of influence.

No assurance can be given that the estimated quantities will be produced. All figures have been rounded to reflect accuracy and to comply with securities regulatory requirements. Summations within the tables may not agree due to rounding.

*The reader is cautioned that a qualified person has not done sufficient work to classify this historical estimate as current resources and Osprey is not treating this historical estimate as a current mineral resource. While this estimate was prepared, in accordance with National Instrument 43-101 and the “Canadian Institute of Mining, Metallurgy and Petroleum Standards on Mineral Resources and Mineral Reserves Definition Guidelines” in effect at the time, there is no guarantee that it would be consistent with current standards and it should not be regarded as consistent with current standards.

**2017 inferred resource includes a near surface and an underground resource with a cut-off of 0.75 g/t and 2.0 g/t respectively.

Footnotes to mineral resource comparison:

The changes are a result of changes to the method of mineral resource estimation and a change in the mineral resource classification. Fladgate’s mineral resource estimate uses a minimum mining width of 2 m, Acadian Gold assumed a minimum mining width of 1.2 m. Acadian’s mineral resource classification used a maximum distance of 25 m to classify Inferred mineral resources whereas Fladgate has used a maximum distance of 35 m. Fladgate also capped high grade assays at 70g/t before compositing whereas Acadian Gold used a 50g/t cap on composited grades.

In addition, Fladgate has applied differing criteria to meet the criteria of reasonable prospects of economic extraction as specified in the CIM Mineral Resource Definition Standards. Fladgate has constrained near surface resources to an L-G optimized pit shell and has constrained underground mineral resources to a grade shell above a grade cut-off incorporating an underground mining cost of $50/t.

Cooper Quinn, President of Osprey said, “I’m very encouraged by this updated resource at Goldenville. It represents a significant increase in our current gold resources. The new digital resource model applies modern 3D estimation techniques to the known deposit publicly for the first time, and will be an excellent guide to our exploration programs as we move forward at Goldenville.”

Resource Estimate

The updated resource includes the results from an additional 8 holes totaling 1,280 meters drilled by Acadian Gold Corporation in 2006 that was completed after the 2005 Acadian Gold Technical Report.

The current mineral resource estimate, effective date March 15, 2017, was prepared by David G. Thomas M.Sc., P. Geo. and Neil Pettigrew M.Sc., P. Geo. using Minesight 3D commercial mining software. Resources were estimated from 150 surface core drillholes and 67 underground channel samples in 4 x 2 x 2 meter blocks by ordinary kriging coded by indicator domain. Fladgate created probabilistic indicator models to progressively constrain the mineralization into domains. Indicator models were estimated using inverse-distance weighting to the power of three (IDW3). Grade estimates were based on capped 2.0 meter composited assay data with a top cut of 70 g/t.

Differences with the previous mineral resource estimate primarily result from changes to the method of mineral resource estimation and from a change in the mineral resource classification. Fladgate has applied differing criteria to meet the criteria of reasonable prospects of economic extraction as specified in the CIM Mineral Resource Definition Standards. Fladgate has constrained near surface mineral resources to an L-G optimized pit shell and has constrained underground mineral resources to a grade shell above a grade cut-off incorporating an underground mining cost of $50/t.

Based upon the marginal gold cut-off grade, Fladgate has chosen a cut-off grade of 0.75 g/t gold for reporting the near surface Mineral Resources. For underground mineral resources, Fladgate estimates a marginal cut-off grade of 2 g/t.

Table 2.1 – Goldenville Mineral Resource and Sensitivities, Near Surface

Cut-Off
Tonnes
Capped Au (g/t)
Capped Au (Oz)
Uncapped Au (g/t)
Uncapped Au (Oz)
0.50
1,370,000
2.79
123,000
4.66
206,000
0.75
1,240,000
3.02
120,000
5.08
203,000
1.00
1,125,000
3.24
117,000
5.49
199,000

Table 2.2 – Goldenville Mineral Resource and Sensitivities, Underground

Cut-Off
Tonnes
Capped Au (g/t)
Capped Au (Oz)
Uncapped Au (g/t)
Uncapped Au (Oz)
2.00
1,560,000
3.35
168,000
4.87
244,000
2.25
1,310,000
3.58
151,000
5.21
220,000
2.50
1,030,000
3.91
130,000
5.68
189,000

The Goldenville Property

The Goldenville Property consists of three contiguous mineral titles totaling approximately 970 ha in Northeastern Nova Scotia. In a news release dated March 2nd, 2017, Osprey announced the closing of an option to acquire a 100% interest in Goldenville (the “Goldenville Transaction”). The Property is under option to Crosby Gold Ltd., a wholly owned subsidiary of Osprey, which retains the right to earn a 100% interest in the claims subject to certain royalties.

Goldenville is located in Guysborough County, approximately 135 km east of Halifax and 3km southwest of the village of Sherbrooke. The Goldenville Gold District, where the Goldenville Property is located, is regarded as one of the most important gold mining districts in Nova Scotia with past gold production between 1862 and 1942 of approximately 212,300 ounces from 551,797 tonnes indicating an historic recovered grade of 11.97 g/t gold.

Technical Report

A technical report, which will include this resource estimate, will be posted on the Company’s website at www.ospreygold.com and filed on SEDAR at www.sedar.com within 45 days. Dave Thomas, M.Sc., P.Geo. and Neil Pettigrew, M.Sc. P.Geo, are both a ‘Qualified Person’ for the purpose of National Instrument 43-101 Standards of Disclosure for Mineral Projects of the Canadian securities administrators (“NI 43-101”). They have both approved the disclosure of, and are the ‘Qualified Person’ responsible for the scientific and technical information in this news release, inclusive of the resource estimate information. They have verified the data disclosed.

ON BEHALF OF OSPREY GOLD DEVELOPMENT LTD.,

“Cooper Quinn”
Cooper Quinn, President and Director

For further information please contact:

Osprey at (236) 521-0944 or cooper@ospreygold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to Osprey within the meaning of applicable securities laws including, without limitation economic estimates and statements related to estimated mining costs.. Osprey provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to exploration findings, results and recommendations in connection with the updated technical report on the Goldenville property, as well as those risks and uncertainties identified and reported in Osprey’s public filings under Osprey’s SEDAR profile at www.sedar.com. Although Osprey has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Osprey disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Osprey Gold Development Ltd.

ReleaseID: 457464

Novus MedPlan to be Offered to AccurateVenture Customers; AccurateVenture’s Hemp Products Now Covered Nationwide Under Novus MedPlan

MIAMI, FL / ACCESSWIRE / March 16, 2017 / Novus Acquisition and Development, Corp. (OTC PINK: NDEV), through its wholly owned subsidiary WCIG Insurance Services, Inc., is a diversified insurance entity in health, liability, annuity and accident, and the nation’s first carrier/aggregator offering a cannabis health plan, today announced a partnership with Golden Grail Technology’s AccurateVenture (OTC PINK: GOGY). Marketing and processing under the Strategic Partnership Agreement is targeted to start in early April 2017.

Novus is proud to announce it has executed a Strategic Partnership Agreement with AccurateVenture, a leading performance-based marketing company. Novus will now cover the bioRenovate ® Pharmaceutical Grade Hemp Cannabidiol products and the consumer Miracle Brand CBD products, under its Novus MedPlan. The Agreement calls for AccurateVenture to offer its approximate 200,000 customers base the opportunity to purchase the Novus MedPlan giving Novus’ patient members up to a 50% discount off the purchase of any of AccurateVenture’s Cannabidiol products.

Novus MedPlan is the nation’s first health plan that focuses on reducing your cost associated with Medical Marijuana and Hemp/CBD (Cannabidiol). This revolutionary service fills the gaps where your insurance policies do not provide coverage or discounts. Novus offers highly affordable plans to people with and without current health insurance. Novus CEO, Frank Labrozzi, stated, “It’s exciting to be working with an industry leader with a significant customer base in the cannabis space. There is no doubt AccurateVenture will help to make Novus MedPlan an even more recognized name and allow us to offer it to a much broader client base.”

“Novus is clearly out in front of the insurance industry in the cannabis space,” stated, AccurateVenture CEO, Bill Fisher. “When I started strategizing back in 2014, I knew one of the most challenging obstacles would be the cost of true pharma-grade product for people without insurance. Novus is an answered prayer for those who use hemp products for health and wellness on a daily basis, and we are excited to get started.”

AccurateVenture is currently in the engineering phase of implementing the sales funnel to adopt the Novus sign-ups into its daily process and the program should launch by early April 2017.

About Golden Grail Technology Corp.

Golden Grail Technology Corp. (GOGY) is a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors such as jewelry, health and personal care, beauty, electronics, pet and animal supplies, sports and games. Golden Grail’s mission is to utilize their network of industry experts, who specialize in targeting areas of business that can be accelerated with technology, in order to give small companies an opportunity to compete with industry giants.

For more information, please visit: http://goldengrailtechnology.com
And: http://accurateventure.com

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.

Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

For more information, please visit: http://www.getnovusnow.com
For NDEV 3rd Quarter Financial Filing: http://bit.ly/2hNHQSg
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355

Investors:
Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: Novus Acquisition & Development Corp.

ReleaseID: 457462

BEND, OR / ACCESSWIRE / March 16, 2017 / RepliCel (OTCQB: REPCF) (TSX-V: RP.V) is a regenerative medicine company focused on developing innovative products for sports medicine and aesthetics markets – degenerated and chronically painful tendons, aging and sun-damaged skin, and hair loss due to androgenetic alopecia.

RepliCel’s products are autologous cell therapies involving a local injection of cells into areas where the need (aging skin, degenerated tendon, hair loss) is related to the resident cells no longer capable of meeting demand. The newly injected cells are being developed and designed to do what’s needed (rejuvenate skin, regenerate tendon, and grow new hair in areas of hair loss).

The conditions RepliCel is actively addressing chronic tendinosis, skin aging, and androgenetic alopecia (pattern baldness). Each disease state is consistent with a deficit of a specific cell type which RepliCel believes is critical to normal function. All treatments under development are based on RepliCel’s innovative technology which utilizes cells isolated from a patient’s own healthy hair follicles. These products are built on RepliCel’s proprietary manufacturing platforms and are covered by issued and filed patents as well as trade secrets. RepliCel is also developing a programmable cell injector device designed for dermal injections of cells, currently approved dermal filler products, and a variety of other products injected through the skin.

The Potential of Autologous Cell Therapy

RepliCel’s treatments use autologous cell therapy (“ACT”), which is one of the most rapidly developing areas of regenerative medicine in the development of novel treatments for numerous human disorders. ACT involves isolating an individual’s own cells from harvested tissues and growing more of those cells, or ‘expanding’ those cells, in controlled conditions in a regulatory compliant manufacturing facility. These purified, expanded cells are then reintroduced to the donor to treat a specific condition. The benefits of autologous (derived from the same person) therapy (as compared to heterologous or derived from a different person) includes minimized risks of systemic immunological (anaphylactic) reactions, bio-incompatibility, and disease transmission. Furthermore, the effects of ACT may be longer lasting than pharmacological or surgical interventions.

Source: Company February Investor Presentation

RCT-01: Treatment for Chronic Tendinosis

Background

Tendinosis refers to a chronic disease of the tendon. It is a function of an imbalance of tendon breakdown and tendon repair initiated first by an injury which does not heal properly. This leads to cycles of compromised repair and subsequent re-injury until such time as there is no healing and a degenerative process has set in. Typically, this chronic condition is linked to aging, overuse, and to general health. We believe that the current standard of care is failing to provide a satisfactory solution to this chronic condition.

Treatment

Chronic tendon injuries resulting from sports-related or occupational overuse are a significant unmet medical need. These are people with frequent or consistent pain in their ankle or Achilles tendon, patellar tendon (jumper’s knee), both tendons of the elbow (Tennis Elbow or Golfer’s Elbow), shoulder (rotator cuff) etc.

Tendons consist of specialized connective tissues that attach muscles to bones. When mechanical loads exceed the strength of a tendon or tensile range is lost due to aging, micro-tears of the collagen fibers within tendon occur. Once a tendon is injured, healing can but does not always occur intrinsically via tenocyte activation within the injured site or extrinsically via recruitment of collagen-producing cells from the surrounding area. Naturally healed tendon does not return to the same physiological state as ‘intact’ tendon, but does allow for normal function. Inadequate rest and improper healing often result in re-injury and rupture. The goal of RepliCel’s injection of cells highly expressive of collagen is to make this healing more efficient and complete.

Current treatments manage pain and facilitate healing processes; however, they do not mediate complete recovery and leave patients demobilized for several months during treatment. RepliCel believes that improved therapeutic strategies are therefore in considerable demand. RepliCel’s fibroblast technology for tendinosis, which RepliCel refers to as RCT-01, has been developed over five years of research, experimentation and trials.

RCT-01 is a tissue-engineered product made from a procedure using collagen-producing fibroblasts isolated from non-bulbar dermal sheath (NBDS) cells within the hair follicle that are replicated in culture. These fibroblasts are efficient producers of type I collagen and because they are of anagen hair follicle mesenchymal origin, they have the potential to replicate efficiently in culture. The use of these fibroblasts is, therefore, ideal for treating chronic tendon disorders that arise due to either a degeneration of collagen producing cells or a deficit of active collagen producing cells.

Because RCT-01 directly provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis, we believe it has advantages over current treatments such as the use of non-steroidal anti-inflammatory medication or corticosteroids which are limited in efficacy. Another advantage of RCT-01 is the autologous nature of the cellular product, thereby reducing the likelihood of adverse immune reactions upon administration.

Phase 1 Clinical Trial

Phase 1 human pilot clinical trials were conducted by RepliCel’s collaborative partner, Dr. David Connell, which focused on tendinosis of the Achilles, patellar and lateral elbow (commonly referred to as tennis elbow) using skin tissue derived fibroblasts. In these trials, where 90 patients were injected with cultured, autologous fibroblasts, no adverse events were reported. RepliCel has expanded on Dr. Connell’s approach by isolating NBDS fibroblasts from the hair follicle that express upwards of five times the amount of type I collagen than fibroblasts derived from skin tissue as pursued by Dr. Connell.

Phase 1/2 Clinical Trial

On December 1, 2014, RepliCel announced Health Canada’s clearance to initiate a Phase 1/2 clinical trial in subjects who have failed traditional tendon treatments and who are otherwise in good health. Trial design was randomized, double-blinded, placebo-controlled with a treatment-to-placebo ration of 3:1. The mechanics of RepliCel’s treatment involve the extraction of hair follicles from the back of a patient’s scalp via a single punch biopsy. NBDS cells are isolated from the hair follicle sheath, replicated in a current Good Manufacturing Practices (cGMP) facility and are then reintroduced under ultrasound guidance directly into the area of damaged tendon. The collagen rich fibroblast cells are expected to initiate and complete the healing of the chronically injured tendon. After injections are performed, subjects will return to the clinic for assessments of safety, function and pain, as well as changes in tendon thickness, echotexture, interstitial tears and neovascularity.

The primary end point is safety while a secondary end point of efficacy is being measured at six months. RepliCel will report data from this trial in the next few days and if the data is positive, RepliCel may have a transformational and highly disruptive therapeutic option, in these indications where no true option exists. The value of this program, assuming safety and efficacy are shown, could be in the billions. RepliCel will pursue further indications of other tendon populations including patellar tendinosis (jumper’s knee) and lateral and medial epicondylitis (tennis and golfer’s elbow).

RCH-01

RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. Dermal sheath cup cells are isolated from a small punch biopsy taken from the back of the subject’s scalp. These cells are replicated and then reintroduced into balding areas on the subject’s scalp. After injections are performed, subjects return to the clinic for assessment of total, terminal and vellus hair density and cumulative hair thickness, as well safety.

On March 15, 2017, RepliCel released data from the Phase I study for RCH-01. The study focused on safety and efficacy, and consisted of 19 patients all of whom suffer androgenetic alopecia. The initial data indicated that the primary endpoint of the trial, safety, was fully achieved, and the secondary endpoint proved highly promising despite the study not being powered for efficacy.

Specifically, to the secondary endpoint, remember, the trial was not powered for (intended to prove) efficacy, regardless the top 10 participants reported at least a 5% or greater increase in hair density at six months’ post-injection with an average increase of 11.8%. This group demonstrated a sustained response at 24 months which averaged a 4.2% increase over baseline hair density. While there was a high degree of variability in hair density between individual participants at 24 months’ post-injection compared to baseline, an overall stabilization of hair loss was observed among all the patients treated per protocol.

Management indicated that RepliCel already has a much more mature product than the one used in this trial, and they anticipate even stronger efficacy results during the Phase II efficacy study, when powered for efficacy. Recent animal studies conducted by the Company have showed increased efficacy by combining smaller doses of RCH-01, with multiple injection sites. Additionally, the Company believes that using the RepliCel injector will increase the consistency of the results.

The Phase I study was conducted at Tokyo Medical University Hospital and Toho University Ohasi Medical Center, by Drs. Tsuboi and Niiyama, and is being financed by the Shiseido Company. Each product being injected will be manufactured by Shiseido at their SPEC (Cell-Processing and Expansion Center) facility in Kobe, Japan. RepliCel helped Shiseido design, validate, and prepare the SPEC facility for certification by Japan’s PMDA (Pharmaceuticals and Medical Device Agency). Shiseido’s SPEC team was also trained by RepliCel and Innovacell in the GMP (Good Manufacturing Practice) compliant production protocols for RCH-01. Data from this trial is expected in the latter half of 2018 and may be sufficient to commercially launch the product in Japan. If this study proves efficacy, this product also may be worth billions of dollars given there are no viable treatment options for mild to moderate androgenetic alopecia (hair loss). Below is an illustration of the hair follicle cycle.

Source: Company February Investor Presentation

Hair Restoration Treatment Options

Medical hair restoration consists of a variety of surgical hair restoration treatments designed to reduce baldness. Follicular unit hair transplant (“FUT”) surgery is by far the dominant hair restoration treatment and involves the surgical removal of large portions of hair-bearing scalp from the back of the head.

These sections of scalp skin are then dissected by hand into smaller hair follicle clusters (follicular units) and transplanted to the balding areas of a patient’s scalp. Scalp flap surgery, scalp reduction surgery and scalp expansion surgery are other forms of surgical hair restoration. Combined, these treatments represent a far smaller patient base than hair transplant surgery.

Follicular unit extraction or (“FUE”) is another type of hair transplant technique in which a small round punch is used to extract follicular units from a patient’s baldness-resistant donor area. These 1, 2, 3 and 4-hair follicular unit grafts are then transplanted into a patient’s balding areas. This is a time consuming and tedious procedure and a physician is often limited to transplanting only 500 to 600 follicular unit grafts in one day which means a patient often has to come in a number of times to achieve the desired result. While the FUE procedure has grown in popularity, largely due to the minimally invasive way in which follicular unit grafts are removed, the standard strip excision method is still the leading hair transplant procedure.

However, FUT and FUE hair transplant surgery will always be limited by the availability and quality of donor hair follicles. Hair replacement surgery is a complicated procedure that may require several hair transplant sessions over a period of one-to-two years before the desired result is achieved. Ultimately, the act of hair transplantation does not ‘create’ new hair. The process simply relocates viable hair from the back of the scalp to the front. Most women will not undergo this extremely invasive surgery. In terms of cosmetic results, both FUT and FUE surgery are quite dependent upon the skill of the surgeon.

Non-Surgical Restoration

Only two hair restoration treatments approved by the United States Food and Drug Administration (“FDA”) are available today: minoxidil and finasteride. Minoxidil is marketed as Rogaine®. Finasteride is marketed as Propecia®. These two products can be effective in hair loss prevention and may grow new hair. However, once a patient begins using Rogaine® or Propecia®, he or she must continue to use the products indefinitely. If an individual stops using the drug, any new hair grown as a result of the drug will likely fall out. As with any drug, adverse reactions can sometimes occur.

Rogaine® (Minoxidil)

Rogaine® (minoxidil) was introduced in 1988 as the first drug approved for treatment of baldness by the FDA. It is now available over-the-counter in several countries including the USA. Minoxidil remains the only product available without a prescription that has been approved by the FDA as a proven treatment against hair loss. Minoxidil is no longer under patent so it is also marketed as a number of topical treatments made by several different companies. Minoxidil stimulates hair growth in individuals with male and female pattern baldness; however, the mechanism of action is unknown. It comes in 2% and 5% topical formulations and known side effects include itching and skin irritation of the treated scalp, as well as unwanted hair in areas adjacent to treatment sites which can be distressing to women when the face is involved. Once treatment is stopped, all results will be lost within 3 to 6 months.

Propecia® (Finasteride)

Finasteride is marketed by Merck under the trademark names Proscar® and Propecia®, among other generic names. It is a synthetic antiandrogen that inhibits type II 5-alpha reductase, the enzyme that converts testosterone to DHT. Only available by prescription, it was developed to treat mild to moderate male pattern hair loss on the vertex (top of head) and anterior mid-scalp area (middle front of head) in men only. There is insufficient evidence that Propecia® works for receding hairlines at the temples. Listed side effects include erectile dysfunction and depression. Once treatment is stopped, all results will be lost within 6 to 12 months.

Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit: http://sylvacap.com/disclaimer

Contact:

info@sylvacap.com

SOURCE: Sylva International LLC

ReleaseID: 457438

AccurateVenture’s Hemp Products Now Covered Nationwide Under Novus MedPlan; Novus MedPlan to be Offered to AccurateVenture Customers

WESTON, FL / ACCESSWIRE / March 16, 2017 / Golden Grail Technology (OTC PINK: GOGY) (“Golden Grail” or the “Company”), a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors, today announced a strategic partnership with insurance provider Novus MedPlan (OTC PINK: NDEV). Marketing and processing under the Strategic Partnership Agreement is targeted to start in early April 2017.

Golden Grail’s wholly-owned subsidiary AccurateVenture is proud to announce it has executed a Strategic Partnership Agreement with Novus MedPlan. Novus will now cover the bioRenovate® Pharmaceutical Grade Hemp Cannabidiol products and the consumer Miracle Brand CBD products, under its Novus MedPlan Insurance Policy.

Novus MedPlan is the nation’s first health plan that focuses on reducing your cost associated with Medical Marijuana and Hemp/CBD (Cannabidiol). This revolutionary service fills the gaps where your insurance policies do not provide coverage or discounts. Novus offers highly affordable plans to people with and without current health insurance. Novus CEO, Frank Labrozzi, stated, “It’s exciting to be working with an industry leader with a significant customer base in the cannabis space. There is no doubt AccurateVenture will help to make Novus MedPlan an even more recognized name and allow us to offer it to a much broader client base.”

The Agreement calls for AccurateVenture to offer its customers an opportunity to purchase the Novus MedPlan insurance right on the checkout page, while purchasing any of AccurateVenture’s Cannabidiol products, simply by checking a box.

“Novus is clearly out in front of the insurance industry in the cannabis space,” stated, AccurateVenture CEO, Bill Fisher. “When I started strategizing back in 2014, I knew one of the most challenging obstacles would be the cost of true pharma-grade product for people without insurance. Novus is an answered prayer for those who use hemp products for health and wellness on a daily basis, and we are excited to get started.”

Although the bioRenovate and Miracle Brands are now officially covered by Novus, AccurateVenture is currently in the web-engineering phase of implementing the sales funnel to adopt the new Novus sign-ups into its daily process. The web program should launch by early April 2017.

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.

Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

For more information, please visit: http://www.getnovusnow.com
For NDEV 3rd Quarter Financial Filing: http://bit.ly/2hNHQSg
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

About Golden Grail Technology Corp.

Golden Grail Technology Corp. (GOGY) is a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors such as jewelry, health and personal care, beauty, electronics, pet and animal supplies, sports and games. Golden Grail’s mission is to utilize their network of industry experts, who specialize in targeting areas of business that can be accelerated with technology, in order to give small companies an opportunity to compete with industry giants.

For more information, please visit: http://goldengrailtechnology.com
And: http://accurateventure.com

Forward-Looking Statements

Except for the historical and present factual information contained in this press release, the matters discussed in this press release, including statements identified by words such as “will,” “expected,” “plans,” and similar expressions are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements, including the factors described in filings with OTC Markets, including but not limited to discussion under the caption “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s judgment solely as of the date hereof.

Contact Information

Hayden IR
(917) 658-7878
hart@haydenir.com

SOURCE: Golden Grail Technology Corp.

ReleaseID: 457463

LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Cardiome Pharma, ProMetic Life Sciences, Cronos Group, and biOasis Technologies. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

On Wednesday, March 15, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,520.91, 0.92% higher, with a total volume of 430,060,332 shares. The TSX Venture Composite Index, on the other hand, closed at 807.28, up 1.82%.

Additionally, the Healthcare index was slightly up by 0.31%, ending the session at 68.62.

Active Wall St. has initiated research reports on the following equities: Cardiome Pharma Corporation (TSX: COM), ProMetic Life Sciences Inc. (TSX: PLI), Cronos Group (TSX-V: MJN), and biOasis Technologies Inc. (TSX-V: BTI). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

Cardiome Pharma Corp.

On Wednesday, shares in Vancouver, Canada-based Cardiome Pharma Corp. recorded a trading volume of 16,864 shares, which was higher than their three months average volume of 9,035 shares. The stock ended the day flat at $4.10. Cardiome Pharma Corp.’s stock has gained 5.13% in the last one month and 15.49% in the previous three months. Shares of the Company, which engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients suffering from heart diseases, are trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $3.92 is above its 200-day moving average of $3.87. See our research report on COM.TO at:

http://www.activewallst.com/register/

ProMetic Life Sciences Inc.

On Wednesday, shares in Laval, Canada headquartered ProMetic Life Sciences Inc. ended the session flat at $2.39 with a total volume of 599,845 shares traded. ProMetic Life Sciences’ shares have gained 21.32% in the past three months. Shares of the Company, which develops bio separations, plasma-derived therapeutics, and small-molecule drugs, are trading above its 50-day moving average. Further, the stock’s 200-day moving average of $2.49 is greater than its 50-day moving average of $2.28. The complimentary research report on PLI.TO at:

http://www.activewallst.com/register/

Cronos Group

Cronos Group’s stock closed the day 2.13% lower at $2.76. The stock recorded a trading volume of 260,981 shares, which was below its three months average volume of 581,215 shares. Cronos Group’s shares have surged 15.00% in the last one month and 76.92% in the past three months. Furthermore, the stock has rallied 1,154.55% in the previous one year. Shares of the Company, which seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations, are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $2.50 is greater than its 200-day moving average of $1.56. Register for free and access the latest research report on MJN.V at:

http://www.activewallst.com/register/

biOasis Technologies Inc.

Richmond, Canada headquartered biOasis Technologies Inc.’s stock advanced 3.61%, to finish Wednesday’s session at $0.86 with a total volume of 26,718 shares traded. Shares of the Company, which operates as a development stage biopharmaceutical company, are trading below its 50-day and 200-day moving averages. biOasis Technologies’ 200-day moving average of $1.30 is above its 50-day moving average of $0.98. Get free access to your research report on BTI.V at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457435

LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Forest Products industry. Companies recently under review include Stella-Jones, Supremex, Domtar, and Tembec. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

At the closing bell on Wednesday, March 15, 2017, the Toronto Exchange Composite index edged 0.92% higher to finish the trading session at 15,520.91 with a total volume of 430,060,332 shares exchanging hands for the day.

Active Wall St. has initiated research reports on the following equities: Stella-Jones Inc. (TSX: SJ), Supremex Inc. (TSX: SXP), Domtar Corporation (TSX: UFS), and Tembec Inc. (TSX: TMB). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

Stella-Jones Inc.

Saint-Laurent, Canada headquartered Stella-Jones Inc.’s stock edged 0.68% lower, to finish Wednesday’s session at $42.20 with a total volume of 220,494 shares traded. Stella-Jones’ shares have advanced 2.68% in the past one month. The Company’s shares are trading above its 50-day moving average. Stella-Jones’ 200-day moving average of $43.43 is above its 50-day moving average of $40.94. Shares of the Company, which produces and markets pressure treated wood products in Canada and the US, are trading at a PE ratio of 17.37. See our research report on SJ.TO at:

http://www.activewallst.com/register/

Supremex Inc.

On Wednesday, shares in LaSalle, Canada-based Supremex Inc. recorded a trading volume of 35,895 shares. The stock ended the day 1.20% lower at $4.93. Supremex’s stock has advanced 1.65% in the past one month. The Company’s shares are trading below its 50-day and 200-day moving averages. The stock’s 200-day moving average of $5.27 is above its 50-day moving average of $5.02. Shares of the Company, which manufactures and sells envelopes, and packaging and specialty products in North America, are trading at PE ratio of 9.69. The complimentary research report on SXP.TO at:

http://www.activewallst.com/register/

Domtar Corp.

On Wednesday, shares in Fort Mill, South Carolina-based Domtar Corp. ended the session 0.26% higher at $50.67 with a total volume of 19,086 shares traded. Domtar’s shares have advanced 3.39% in the past one year. The stock is trading below its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $53.19 is greater than its 200-day moving average of $51.14. Shares of Domtar, which designs, manufactures, markets, and distributes communication papers, specialty and packaging papers, and absorbent hygiene products in the US, Canada, Europe, Asia, and internationally, are trading at a PE ratio of 24.84.

Register for free and access the latest research report on UFS.TO at:

http://www.activewallst.com/register/

Tembec Inc.

Montreal, Canada headquartered Tembec Inc.’s stock closed the day 1.36% lower at $2.91. The stock recorded a trading volume of 186,749 shares, which above its three months average volume of 110,280 shares. Tembec’s shares have surged 75.30% in the last three months and 216.30% in the past one year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $2.89 is greater than its 200-day moving average of $1.82. Shares of the Company, which produces and sells forest products in Canada, the US, China, the European Union, and internationally, are trading at a PE ratio of 7.46. Get free access to your research report on TMB.TO at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457437

VANCOUVER, BC / ACCESSWIRE / March 16, 2017 / CVR Medical Corp. (TSX-V: CVM) (FSE: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces partnership with ADCO Circuits, a Michigan-based electronic design and manufacturing company. ADCO will be the exclusive provider of the custom circuit board inside the sensor of CVR’s “Carotid Stenotic Scan (CSS)” device.

ADCO Circuits is a certified ISO 9002, ISO AS9100, and ISO TS16949 manufacturer of electronic assemblies and full system box builds. With over 35 years of experience, they are recognized as industry leaders capable of managing projects from prototype to volume production. Their involvement with CVR ensures quality and reliability for one of the vital components in the testing module of the CSS. ADCO’s state-of-the-art manufacturing facility, located in Rochester Hills, MI, allows for maximum efficiency in the full-scaled production process CVR will require. CVR Global COO Tony Robinson states, “Our work with ADCO has been an integral part of creating such a technically sound device. We’re proud of that, and it is indicative of the incredible reputation they’ve developed and earned.”

On their work on the CSS, ADCO Executive Officer, Marc Damman states, “We’ve been looking forward to seeing this project through to its launch, and being alongside CVR in the future as they expand beyond this product. They’ve created game-changing technology, and we’re excited to be a part of it.”

For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com.

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
(signed) “Peter Bakema”
CEO, President & Director

For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: CVR Medical Corp.

ReleaseID: 457461

LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Oil & Gas – E&P industry. Companies recently under review include US Oil Sands, Canadian Overseas Petroleum, Pennine Petroleum, and Blackbird Energy. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

At the close of the Canadian markets on Wednesday, March 15, 2017, the TSX Venture Composite index ended the trading session at 807.28, 1.82% higher from its previous closing price.

The Energy Index was also in the black, closing the day at 200.08, up 2.96%.

Active Wall St. has initiated research reports on the following equities: US Oil Sands Inc. (TSX-V: USO), Canadian Overseas Petroleum Ltd (TSX-V: XOP), Pennine Petroleum Corporation (TSX-V: PNN), and Blackbird Energy Inc. (TSX-V: BBI). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

US Oil Sands Inc.

On Wednesday, shares in Calgary, Canada headquartered US Oil Sands Inc. ended the session 16.25% higher at $0.93 with a total volume of 9,470 shares traded. Shares of the Company, which explores for and develops oil sands properties in the US, are trading below its 50-day and 200-day moving averages. Furthermore, the stock’s 200-day moving average of $1.45 is greater than its 50-day moving average of $1.09. See our research report on USO.V at:

http://www.activewallst.com/register/

Canadian Overseas Petroleum Ltd

Calgary, Canada headquartered Canadian Overseas Petroleum Ltd’s stock closed the day 25.00% at $0.03. The stock recorded a trading volume of 77,000 shares. Shares of the Company, which together with its subsidiaries, engages in the identification, acquisition, exploration, and development of oil and natural gas offshore reserves in sub-Saharan Africa, are trading above their 50-day moving average. Moreover, the stock’s 200-day moving average of $0.09 is greater than its 50-day moving average of $0.02. The complimentary research report on XOP.V at:

http://www.activewallst.com/register/

Pennine Petroleum Corp.

Calgary, Canada headquartered Pennine Petroleum Corp.’s stock surged 10.00%, to finish Wednesday’s session at $0.05 with a total volume of 219,000 shares traded. Over the last one month and the previous three months, Pennine Petroleum’s shares have gained 20.00%, each. Furthermore, the stock has rallied 100.00% in the past one year. Shares of the Company, which engages in the evaluation, acquisition, exploration, and development of oil and gas properties in Western Canada, are trading above its 200-day moving average. Pennine Petroleum’s 50-day moving average of $0.05 is above its 200-day moving average of $0.04. Register for free and access the latest research report on PNN.V at:

http://www.activewallst.com/register/

Blackbird Energy Inc.

On Wednesday, shares in Calgary, Canada headquartered Blackbird Energy Inc. recorded a trading volume of 836,998 shares. The stock ended the day flat at $0.53. Blackbird Energy’s stock has rallied 253.33% in the past one year. The Company’s shares are trading above its 200-day moving average. The stock’s 50-day moving average of $0.60 is above its 200-day moving average of $0.49. Shares of the Company, which engages in the exploration, development, and production of crude oil and natural gas in western Canada, are trading at PE ratio of 106.00. Get free access to your research report on BBI.V at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457436

VANCOUVER, BC / ACCESSWIRE / March 16, 2017 / Power Americas Minerals Corp. (TSX-V: PAM) (“Power Americas” or the “Company”) is pleased to announce that the Province of Alberta has approved Power America’s application for 100% undivided interest in a further six metallic and industrial minerals exploration permits covering six townships northwest of the Fox Creek-Swan Hills district in the Peace River Arch-Spirit River area of northwestern Alberta.

These additional six exploration permits are contiguous to the previous four townships that were acquired by Power Americas in August 2016. Power America’s collective northwestern Alberta land package now has a total of 10 adjoining exploration permits covering more than 90,000 hectares (222,395 acres) or 900 square kilometres. The newly acquired permits contain more than 1000 well sites including more than 200 new and deep-basin wells that were drilled since 2010. The Spirt River project now contains potential access to more than 1900 wells, some of which contain elevated lithium-brine values as documented historically in publicly available Government of Alberta reports. Power America’s exploration focus will include test assaying brine samples from the new, deep-basin wells representing virgin ground that has never been tested for the lithium-in-brine content, signifying a new target of exploration for the Company and its shareholders.

Note: To date, the company and its Qualified Professionals have been unable to verify the historical lithium-brine results and whether the lithium-enriched brine occurs, or extends, into aquifers underlying the Spirit River property.

Power America’s initial Exploration Program (see news release 01-11-17) is underway on the Spirit River Lithium Project. Local area petro-operators have granted access and brine sampling will be collected from approximately 20-30 separate producing wells. The brine samples will be tested for potentially elevated concentrations of lithium and other important elements in brine reservoirs/aquifers underlying Spirit River landholdings. Further results will be released as they become available.

The Company’s consultant, APEX Geoscience Ltd. of Edmonton AB, is supervising and conducting the brine sampling program in conjunction with several oil and gas producers in the region. The brine samples collected will undergo geochemical analysis by Maxxam Analytics Inc. at its Petroleum Technology Centre located in Edmonton, AB.

About Power Americas Mineral Corp.

Power America’s acquisition strategy focuses on acquiring affordable, cost effective and highly regarded mineral properties in areas with proven geological potential. These areas include historical and currently producing mines with existing infrastructure. This strategy includes acquiring 100% interests in mineral properties, with no payment terms or work program commitments that would threaten a junior mining company’s financial stability. The Company believes it can create maximum shareholder value efficiently and cost effectively implementing this acquisition strategy.

Power Americas believes that the demand profile for Lithium, Cobalt and other essential power related materials will be fundamentally led by the growing adaptation of electric vehicles, renewable energy and increased production of super alloys. With a focus on identifying and developing ethically sourced materials within the Americas, the Company intends to address the growing demand for energy metals that are being driven by innovation and the introduction of new technologies.

Power Americas Minerals Corp. is a Canadian-based junior mining exploration company focused on the procurement, exploration and development of cobalt, lithium, copper and other energy metals in North and South America. The Company’s shares are listed and posted for trading on the TSX Venture Exchange under the symbol “PAM” and on the Frankfurt Exchange under the symbol “VV0”.

The technical content of this news release has been reviewed and approved by Roy Eccles MSc, P Geol, of APEX Geoscience Ltd., an independent qualified person as defined by National Instrument 43-101.

On behalf of the Board of Directors:

“Jeffrey Cocks”

Jeffrey Cocks
President

For more information please contact:
Howard Milne V.P. Business Development
Tel: (604) 377-8994 Email: hdmcap@shaw.ca
Website: www.poweramericascorp.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION IN THE UNITED STATES

SOURCE: Power Americas Mineral Corp.

ReleaseID: 457460

Upcoming AWS Coverage on Medtronic Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. blog coverage looks at the headline from Cesca Therapeutics Inc. (NASDAQ: KOOL) as the Company reported on March 15, 2017, encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers. Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Cesca Therapeutics’ competitors within the Medical Appliances & Equipment space, Medtronic PLC (NYSE: MDT), reported on February 21, 2017, its financial results for Q3 FY17, which ended January 27, 2017. AWS will be initiating a research report on Medtronic in the coming days.

Today, AWS is promoting its blog coverage on KOOL; touching on MDT. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Study

Cesca Therapeutics stated that the study was conducted with 24 patients with one wound/ulcer of varying etiology were treated with a single dose of PRP injections around the wound alongside a topical administration of autologous platelet gel. The process was completed at the patient’s bedside in a single session within 30 minutes. The Company noted that healing of the wound/ulcer was observed in patients as early as 4 weeks after the PRP treatment with a mean healing time of 8.2 weeks ±1.9. All patients demonstrated healing of the wound/ulcer, with 17 (70.8%) patients showing a 90% reduction in wound size and 3 (12.5%) patients showing an 80-90% reduction over the course of the 24 week follow-up. The study also reported that there were no adverse events on the day of treatment or during the patient’s 24 week follow-up, demonstrating a good safety profile for the treatment of chronic non-healing wounds/ulcers.

Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX commented:

“We are very pleased with the data from the study and believe that the use of PRP is a major breakthrough for the treatment of chronic non-healing wounds and ulcers. Using Cesca’s point-of-care platform, we are able to develop rapid cell based therapies at the patient’s bedside within 30 minutes significantly reducing the risk and costs associated with current standard of care treatments.”

Chronic non-healing ulcers pose a significant health risk worldwide affecting an estimated 2 million-6 million people in the United States alone, and are a major cause of non-traumatic lower limb amputations. Despite a variety of standard of care treatments, many chronic ulcers fail to heal or persist for months/years and/or recur after healing, requiring additional advanced wound care therapies. Platelet Rich Plasma, however, has been a major breakthrough in the arena of vascular therapies allowing the use of a patient’s own body cells for wound/ulcer treatment, providing the necessary growth factors that enhance tissue healing.

$5 Million Line of Credit

On March 13, 2017, Cesca Therapeutics announced that it has closed a revolving line of credit (“RLOC”) with Boyalife Investment Fund II, Inc. The non-collaterized RLOC is for a term of five years and is generally drawable at Cesca’s discretion. Additionally, Cesca also announced that it has set-up a wholly-owned subsidiary, ThermoGenesis Corp., to separately own and operate, and thereby strengthen its device business. The clinical development activities will remain with Cesca, the parent Company.

“This RLOC with Boyalife gives us the financial resources to offer our expanding product pipeline to new and existing customers in the US and international markets without having to dilute the Company’s stockholders at current market price,” said Chris Xu, Cesca’s interim Chief Executive Officer, “Automation in cellular processing and a point-of-care therapy is the core business for ThermoGenesis. Setting up the device division in in its own entity is intended to enable Cesca to more effectively manage the device business’s performance and growth strategy. Our goal is to make ThermoGenesis cash-flow neutral within next 12 months.”

Stock Performance

At the close of trading session on Wednesday, March 15, 2017, following the announcement, Cesca Therapeutics’ stock price rose 8.36% to end the day at $3.11. A total volume of 3.07 million shares were exchanged during the session, which was above the 3-month average volume of 182.57 thousand shares. At Wednesday’s closing price, the stock’s net capitalization stands at $30.79 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457433